Patents by Inventor Norihisa MIKAMI

Norihisa MIKAMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230111840
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Application
    Filed: December 7, 2022
    Publication date: April 13, 2023
    Applicants: Kyoto University, Astellas Pharma Inc.
    Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI
  • Patent number: 11578067
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 14, 2023
    Assignees: KYOTO UNIVERSITY, ASTELLAS PHARMA INC.
    Inventors: Shimon Sakaguchi, Naganari Ohkura, Norihisa Mikami, Shuh Narumiya, Masahiko Akamatsu, Guliang Xia, Hironori Harada, Naoto Nakamura, Satoru Ujihara, Hisao Hamaguchi
  • Publication number: 20210238551
    Abstract: Provided is a method for producing regulatory T cells, comprising the step of culturing mammalian-derived peripheral T cells in a medium comprising TGF? and IL-2 in the presence of CD3 stimulation and in the absence of CD28 stimulation. The medium may further comprise ascorbic acid. The method may further comprise the step of culturing the obtained cell culture in a medium comprising IL-2.
    Type: Application
    Filed: August 21, 2019
    Publication date: August 5, 2021
    Applicant: Osaka University
    Inventors: Shimon Sakaguchi, Norihisa Mikami
  • Publication number: 20200095549
    Abstract: Provided is a method for inducing regulatory T cells, comprising a step of inhibiting the expression of Satb1 or the function of Satb1 in peripheral conventional T cells.
    Type: Application
    Filed: December 19, 2017
    Publication date: March 26, 2020
    Inventors: Shimon SAKAGUCHI, Yohko KITAGAWA, Norihisa MIKAMI
  • Publication number: 20190382403
    Abstract: Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3+ T cells can be induced by treating Foxp3? T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.
    Type: Application
    Filed: January 30, 2018
    Publication date: December 19, 2019
    Applicants: Kyoto University, Astellas Pharma Inc.
    Inventors: Shimon SAKAGUCHI, Naganari OHKURA, Norihisa MIKAMI, Shuh NARUMIYA, Masahiko AKAMATSU, Guliang XIA, Hironori HARADA, Naoto NAKAMURA, Satoru UJIHARA, Hisao HAMAGUCHI